Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

Overview of attention for article published in Journal of Clinical Oncology, May 2016

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news: 5 news outlets
blogs: 1 blog
policy: 2 policy sources
twitter: 32 X users

patent: 19 patents
facebook: 4 Facebook pages
guideline: 1 clinical guideline source

Readers on

mendeley: 534 Mendeley

So far, Altmetric has seen 2 policy documents that reference this research output.

Ibrance (with Faslodex) for Advanced or Metastatic Breast Cancer – Details - Palbociclib (Ibrance) Fulvestrant MBC – Final Clinical Guidance Report

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 28 Sep 2018

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer: Committee papers

Cited by National Institute for Health and Care Excellence (NICE) on 09 Nov 2017

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity.